Download PDF
Facial Plast Surg 2019; 35(04): 368-376
DOI: 10.1055/s-0039-1695044
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Oncodermatology of the Head and Neck

W. Martin C. Klop
1   Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
,
Yannick S. Elshot
2   Department of Dermatology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
3   Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
,
Ann-Jean C. C. Beck
1   Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
,
Renate E. Brandsen
4   Department of Dermatology, Mohs Klinieken Amsterdam, Amsterdam, The Netherlands
,
Peter J. F. M. Lohuis
1   Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
30 August 2019 (online)

Also available at
    Permissions and Reprints

Abstract

The European Academy of Facial Plastic Surgery celebrates its 40th anniversary. We aimed to describe innovations in the diagnostics and treatment in head and neck skin cancer over the past 40 years as well as future perspectives. Landmark events, developments, and highlights over the past decades for basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma are discussed.

Keywords

skin cancer - elderly patient - sentinel node biopsy - diagnostic - neoadjuvant immunotherapy
 

  • References

  • 1 Cutaneous Malignancies of the Head and Neck. Lohuis PJFM, de Rie MA, Balm AJM. In: Facial plastic and reconstructive surgery. Great Britain: Hodder Arnold; 2006:383–409
    PubMed
  • 2 Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30 (5 Pt 1): 774-778
    CrossrefPubMedGoogle Scholar
  • 3 Gloster Jr HM, Brodland DG. The epidemiology of skin cancer. Dermatol Surg 1996; 22 (03) 217-226
    CrossrefPubMedGoogle Scholar
  • 4 Bernstein SC, Lim KK, Brodland DG, Heidelberg KA. The many faces of squamous cell carcinoma. Dermatol Surg 1996; 22 (03) 243-254
    PubMedGoogle Scholar
  • 5 Strom SS, Yamamura Y. Epidemiology of nonmelanoma skin cancer. Clin Plast Surg 1997; 24 (04) 627-636
    CrossrefPubMedGoogle Scholar
  • 6 Miller SJ, ed. Cutaneous Oncology: Pathophysiology, Diagnosis, and Management. Madden, USA: Blackwell Science; 1998
    PubMed
  • 7 Rigel DS, Friedman RJ, Kopf AW. Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. J Am Acad Dermatol 1996; 35 (06) 1012-1013
    CrossrefPubMedGoogle Scholar
  • 8 Scotto J, Kopf AW, Urbach F. Non-melanoma skin cancer among Caucasians in four areas of the United States. Cancer 1974; 34 (04) 1333-1338
    CrossrefPubMedGoogle Scholar
  • 9 Weinstock MA, Bogaars HA, Ashley M, Litle V, Bilodeau E, Kimmel S. Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol 1991; 127 (08) 1194-1197
    CrossrefPubMedGoogle Scholar
  • 10 Urbach F. Ultraviolet radiation and skin cancer of humans. J Photochem Photobiol B 1997; 40 (01) 3-7
    CrossrefPubMedGoogle Scholar
  • 11 Copeland NE, Hanke CW, Michalak JA. The molecular basis of xeroderma pigmentosum. Dermatol Surg 1997; 23 (06) 447-455
    PubMedGoogle Scholar
  • 12 Ducloux D, Carron P-L, Rebibou J-M. , et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65 (09) 1270-1272
    CrossrefPubMedGoogle Scholar
  • 13 Jacob A. Observations respecting an ulcer of peculiar character, which attacks the eye-lids and other parts of the face. Dubl Hosp Rep 1827; 4: 232-239
    PubMedGoogle Scholar
  • 14 Flohil SC, de Vries E, Neumann HA, Coebergh J-W, Nijsten T. Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011; 91 (01) 24-30
    CrossrefPubMedGoogle Scholar
  • 15 Flohil SC, Seubring I, van Rossum MM, Coebergh J-WW, de Vries E, Nijsten T. Trends in Basal cell carcinoma incidence rates: a 37-year Dutch observational study. J Invest Dermatol 2013; 133 (04) 913-918
    CrossrefPubMedGoogle Scholar
  • 16 Flohil SC, Koljenović S, de Haas ER, Overbeek LI, de Vries E, Nijsten T. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. Br J Dermatol 2011; 165 (04) 874-881
    CrossrefPubMedGoogle Scholar
  • 17 Flohil SC, van Tiel S, Koljenović S. , et al. Frequency of non-histologically diagnosed basal cell carcinomas in daily Dutch practice. J Eur Acad Dermatol Venereol 2013; 27 (07) 907-911
    CrossrefPubMedGoogle Scholar
  • 18 Rippey JJH. Why classify basal cell carcinomas?. Histopathology 1998; 32 (05) 393-398
    CrossrefPubMedGoogle Scholar
  • 19 Nederlandse Vereniging voor Dermatologie en Venereologie. Evidence-based Richtlijn Basaalcarcinoom [modulaire update 2015]. Available at: http://www.nvdv.nl/wp-content/uploads/2014/08/20160725-eindversie-richtlijn-BCC-2015.pdf . Accessed July 11, 2019
    PubMedGoogle Scholar
  • 20 Telfer NR, Colver GB, Bowers PW. ; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol 1999; 141 (03) 415-423
    CrossrefPubMedGoogle Scholar
  • 21 Gulleth Y, Goldberg N, Silverman RP, Gastman BRJP. What is the best surgical margin for a basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 2010; 126 (04) 1222-1231
    CrossrefPubMedGoogle Scholar
  • 22 Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88 (02) 167-179
    PubMedGoogle Scholar
  • 23 Arits AH, Schlangen MH, Nelemans PJ, Kelleners-Smeets NW. Trends in the incidence of basal cell carcinoma by histopathological subtype. J Eur Acad Dermatol Venereol 2011; 25 (05) 565-569
    CrossrefPubMedGoogle Scholar
  • 24 Kadouch DJ, van Haersma de With A, Limpens J. , et al. Is a punch biopsy reliable in subtyping basal cell carcinoma? A systematic review. Br J Dermatol 2016; 175 (02) 401-403
    CrossrefPubMedGoogle Scholar
  • 25 Fercher AF, Mengedoht K, Werner W. Eye-length measurement by interferometry with partially coherent light. Opt Lett 1988; 13 (03) 186-188
    CrossrefPubMedGoogle Scholar
  • 26 Schmitt JM, Yadlowsky MJ, Bonner RF. Subsurface imaging of living skin with optical coherence microscopy. Dermatology 1995; 191 (02) 93-98
    CrossrefPubMedGoogle Scholar
  • 27 Mogensen M, Nürnberg BM, Forman JL, Thomsen JB, Thrane L, Jemec GB. In vivo thickness measurement of basal cell carcinoma and actinic keratosis with optical coherence tomography and 20-MHz ultrasound. Br J Dermatol 2009; 160 (05) 1026-1033
    CrossrefPubMedGoogle Scholar
  • 28 González S, Tannous Z. Real-time, in vivo confocal reflectance microscopy of basal cell carcinoma. J Am Acad Dermatol 2002; 47 (06) 869-874
    CrossrefPubMedGoogle Scholar
  • 29 Guitera P, Menzies SW, Longo C, Cesinaro AM, Scolyer RA, Pellacani G. In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. J Invest Dermatol 2012; 132 (10) 2386-2394
    CrossrefPubMedGoogle Scholar
  • 30 Kadouch DJ, Schram ME, Leeflang MM, Limpens J, Spuls PI, de Rie MA. In vivo confocal microscopy of basal cell carcinoma: a systematic review of diagnostic accuracy. J Eur Acad Dermatol Venereol 2015; 29 (10) 1890-1897
    CrossrefPubMedGoogle Scholar
  • 31 Duinkerken CW, Lohuis PJ, Heemsbergen WD. , et al. Orthovoltage for basal cell carcinoma of the head and neck: excellent local control and low toxicity profile. Laryngoscope 2016; 126 (08) 1796-1802
    CrossrefPubMedGoogle Scholar
  • 32 Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978; 38 (08) 2628-2635
    PubMedGoogle Scholar
  • 33 Collier NJ, Haylett AK, Wong TH. , et al. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis. Br J Dermatol 2018; 179 (06) 1277-1296
    CrossrefPubMedGoogle Scholar
  • 34 Arits AH, Mosterd K, Essers BA. , et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14 (07) 647-654
    CrossrefPubMedGoogle Scholar
  • 35 Mohs FE. Chemosurgery: a microscopically controlled method of cancer excision. Head Neck Surg 1941; 42 (02) 279-295
    PubMedGoogle Scholar
  • 36 Tromovitch T, Stegeman SJ. Microscopically controlled excision of skin tumors. Arch Dermatol 1974; 110 (02) 231-232
    CrossrefPubMedGoogle Scholar
  • 37 Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol 2009; 8 (10) 914-922
    PubMedGoogle Scholar
  • 38 van Loo E, Mosterd K, Krekels GA. , et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer 2014; 50 (17) 3011-3020
    CrossrefPubMedGoogle Scholar
  • 39 Koelblinger P, Lang R. New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib. OncoTargets Ther 2018; 11: 8327-8340
    PubMedGoogle Scholar
  • 40 Gorlin RJ. Nevoid basal cell carcinoma syndrome. Medicine (Baltimore) 1987; 66 (02) 98-113
    PubMedGoogle Scholar
  • 41 Sekulic A, Migden MR, Oro AE. , et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366 (23) 2171-2179
    CrossrefPubMedGoogle Scholar
  • 42 Falto-Aizpurua L, Griffith R, Simmons B, Nouri K. The history of skin cancer. J Am Acad Dermatol 2015; 72 (5, suppl 1): AB 27
    PubMedGoogle Scholar
  • 43 Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol 2013; 68 (06) 957-966
    CrossrefPubMedGoogle Scholar
  • 44 World Health Organization. Ageing and Health Report online 5-2-2018.
    PubMed
  • 45 Dutch Cancer Registry (in Dutch). Available at: www.cijfersoverkanker.nl . Accessed July 11, 2019
    PubMed
  • 46 Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for nonmelanoma skin cancer treatment, part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 2015; 41 (11) 1214-1240
    CrossrefPubMedGoogle Scholar
  • 47 Brantsch KD, Meisner C, Schönfisch B. , et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9 (08) 713-720
    CrossrefPubMedGoogle Scholar
  • 48 Moore BA, Weber RS, Prieto V. , et al. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope 2005; 115 (09) 1561-1567
    CrossrefPubMedGoogle Scholar
  • 49 Rowe DE, Carroll RJ, Day Jr CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26 (06) 976-990
    CrossrefPubMedGoogle Scholar
  • 50 Karia PS, Morgan FC, Califano JA, Schmults CD. Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC cancer staging manual. JAMA Dermatol 2018; 154 (02) 175-181
    CrossrefPubMedGoogle Scholar
  • 51 Sood A, Wykes J, Roshan D. , et al. A critical analysis of the prognostic performance of the 8th edition American Joint Committee on Cancer staging for metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck 2019; 41 (06) 1591-1596
    CrossrefPubMedGoogle Scholar
  • 52 Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion. J Am Acad Dermatol 2005; 53 (02) 261-266
    CrossrefPubMedGoogle Scholar
  • 53 Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013; 347: f6153
    CrossrefPubMedGoogle Scholar
  • 54 Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol 2012; 106 (07) 811-815
    CrossrefPubMedGoogle Scholar
  • 55 Ebrahimi A, Moncrieff MD, Clark JR. , et al. Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary. Head Neck 2010; 32 (10) 1288-1294
    CrossrefPubMedGoogle Scholar
  • 56 Ebrahimi A, Clark JR, Lorincz BB, Milross CG, Veness MJ. Metastatic head and neck cutaneous squamous cell carcinoma: defining a low-risk patient. Head Neck 2012; 34 (03) 365-370
    CrossrefPubMedGoogle Scholar
  • 57 Maubec E, Petrow P, Scheer-Senyarich I. , et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29 (25) 3419-3426
    CrossrefPubMedGoogle Scholar
  • 58 Migden MR, Rischin D, Schmults CD. , et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379 (04) 341-351
    CrossrefPubMedGoogle Scholar
  • 59 Lane-Brown M, Roxanas MG. Laennec’s melanosis: The first published description of metastatic melanoma. Australas J Dermatol 2017; 58 (03) 234-235
    CrossrefPubMedGoogle Scholar
  • 60 Veronesi U, Adamus J, Bandiera DC. , et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297 (12) 627-630
    CrossrefPubMedGoogle Scholar
  • 61 Balch CM, Soong S-J, Bartolucci AA. , et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224 (03) 255-263 , discussion 263–266
    CrossrefPubMedGoogle Scholar
  • 62 Morton DL, Wen D-R, Wong JH. , et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127 (04) 392-399
    Google Scholar
  • 63 Morton DL, Thompson JF, Cochran AJ. , et al; MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355 (13) 1307-1317
    CrossrefPubMedGoogle Scholar
  • 64 van Akkooi AC, de Wilt JH, Verhoef C. , et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42 (03) 372-380
    CrossrefPubMedGoogle Scholar
  • 65 Faries MB, Thompson JF, Cochran AJ. , et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376 (23) 2211-2222
    CrossrefPubMedGoogle Scholar
  • 66 Hodi FS, O'Day SJ, McDermott DF. , et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363 (08) 711-723
    CrossrefPubMedGoogle Scholar
  • 67 Eggermont AM, Chiarion-Sileni V, Grob J-J. , et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375 (19) 1845-1855
    CrossrefPubMedGoogle Scholar
  • 68 Weber J, Mandala M, Del Vecchio M. , et al; CheckMate 238 Collaborators. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377 (19) 1824-1835
    CrossrefPubMedGoogle Scholar
  • 69 Eggermont AMM, Blank CU, Mandala M. , et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378 (19) 1789-1801
    CrossrefPubMedGoogle Scholar
  • 70 Gershenwald JE, Scolyer RA, Hess KR. , et al. Melanoma of the skin. In: Amin M, Edge SB, Greene FL. , et al, eds. AJCC Cancer Staging Manual, 8th ed. Cham, Switzerland: Springer; 2017
    Google Scholar
  • 71 Gershenwald JE, Scolyer RA, Hess KR. , et al; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67 (06) 472-492
    CrossrefPubMedGoogle Scholar
  • 72 de Souza ALR, LaRochelle E, Marra K. , et al. Assessing daylight & low-dose rate photodynamic therapy efficacy, using biomarkers of photophysical, biochemical and biological damage metrics in situ. Photodiagn Photodyn Ther 2017; 20: 227-233
    CrossrefPubMedGoogle Scholar
  • 73 Rozeman EA, Menzies AM, van Akkooi ACJ. , et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019; 20 (07) 948-960
    CrossrefPubMedGoogle Scholar